Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

RVC Biofund Portfolio Company to Contribute to Development of Cancer Therapy

Published: Thursday, February 21, 2013
Last Updated: Thursday, February 21, 2013
Bookmark and Share
The investment committee of RVC Biofund has approved the investment in Andrus Reo, a recently established startup which will conduct phase III clinical trials for an antineoplastic drug in Russia and the CIS.

The Reovirus based anti-cancer drug, which is being jointly developed with Oncolytics Biotech Inc. of Canada, targets the treatment of head and neck malignant tumors as well as pancreatic cancer. The investment in Andrus Reo in addition to supporting the phase II clinical trials will also assist with further registration of the drug.

According to the Russian Federation Ministry of Health, the rate of pancreatic cancer has been steadily increasing for the last two decades. Pancreatic cancer was diagnosed at 9.05 cases per 100,000 individuals in 2000, 10.59 cases per 100,000 in 2011, and is expected to reach 11 cases per 100,000 by 2015. The survival rate of pancreatic cancer remains one of the lowest in oncology due to lack of effective treatment. While the statistics concerning head and neck malignant tumor statistics are not as severe, they continue to be a significant concern of the Russian people and burden on the Russian healthcare system.

“Despite considerable achievements in the last 30 years in chemotherapy the problem of new malignant neoplasms therapy is still of acute interest and the attention of venture investors to develop and market projects of new antineoplastic medication is growing as well. This unprecedented project, launched by Andrus Ltd. and RVC Biofund in cooperation with Oncolytics Biotech Inc., involves unique scientific and experimental foundation of the Canadian company and advanced clinical research data. The transfer of innovative developments at such a stage is an unparalleled precedent for the Russian pharmaceutical R&D sector,” said Egor Beketov, Director of RVC Biofund. “We hope to make this drug available for Russian patients and significantly improve their the quality of life as well as lay the groundwork for the new development of products on the basis of oncolytic viruses”

The development is a Reovirus which selectively infects and destroys the cells with activated RAS pathway. Hyperactivation of the RAS signaling pathway is the root cause of many cancers (up to 30 % of all carcinomas) and is found in metastases in 85-90 % of all cases. Tumors bearing an activated RAS pathway are deficient in their ability to activate an anti-viral response mediated by the host cellular protein, PKR. Since PKR is responsible for preventing reovirus replication, tumor cells that lack the activity of PKR are susceptible to Reovirus infection and eventual cell death. As normal cells do not possess RAS activation, these cells are able to thwart Reovirus infection by the activity of PKR.

“The drug is a proprietary formulation of the human Reovirus and is a key development of Oncolytics Biotech Inc. We carry out multi-center randomized clinical studies of this drug for a variety of indicators in oncology and hope the development of a commercial product will improve the efficiency of treatment of a wide range of malignant neoplasms. Cooperation with RVC Biofund and Andrus Ltd provides us a unique opportunity to market the product both in Russia and the CIS countries,” said Brad Thompson, Chief Executive Officer of Oncolytics Biotech Inc.

Konstantin Chernov, General Director of Andrus Reo added, “The medicine targets a wide range of tumors and has a potential to become a blockbuster in its segment. Limited (compared to traditional chemotherapy) side effects and unique mechanism of action allows the combination of the drug with different anti-neoplastic agents thus increasing the efficacy of treatment with excellent tolerability. The effects were proven in a cycle of phase II clinical trials of different cancers, including head and neck cancer.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
NIH Study Finds Calorie Restriction Lowers Some Risk Factors for Age-Related Diseases
Two-year trial did not produce expected metabolic changes, but influenced other life span markers.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Computerized Flexible Needles Prove Themselves in Biological Tissue
The advantage of the system is that you can avoid obstacles with the needles or critical tissues and that the system during the insertion of the needle in real time can adjust the path if, for example, the tissue deforms.
DARWIN 2 24-week Monotherapy Data in RA Confirm Previous Results
Safety profile in DARWIN 2 consistent with previous filgotinib RA studies.
Researchers Publish Landmark “Basket Study”
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.
Agricultural Intervention Improves HIV Outcomes
A multifaceted farming intervention can reduce food insecurity while improving HIV outcomes in patients in Kenya, according to a randomized, controlled trial led by researchers at UC San Francisco.
Overdose of Vitamin D in Teenagers May Lead to Increased Cholesterol Levels
Dosing obese teens with vitamin D shows no benefits for their heart health or diabetes risk, and could have the unintended consequences of increasing cholesterol and fat-storing triglycerides. These are the latest findings in a series of Mayo Clinic studies in childhood obesity.
Phase 2 Trials Underway for New Single Dose Malaria Treatment
The new drug, which prevents the malaria parasite from reproducing and spreading, is now undergoing Phase II clinical trials in humans.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!